27
total announcements
JUBLPHARMA.NS · 15 min delayed
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication - Re-lodgement and KYC Updation, including special window for re-lodgement of transfer request of Physical Shares and KYC Updation and dematerialization of physical share certificates.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about receiving a Show Cause Notice from the Joint Commissioner, CGST Division, Roorkee, proposing demand of GST, Interest and penalty for the Financial Year 2020-21 to 2021-2022.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 26, 2026, and submitted the Exchange a copy of Srutinizers report along with voting results.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has received USFDA approval for its new Isolator-based fill and finish line, Line 3, at its Contract manufacturing facility in Spokane, U.S.A.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has announced the outcome of its postal ballot, where shareholders have approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, with the requisite majority.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has submitted copies of published unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the NSE, as per Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has announced its financial results for the quarter ended June 30, 2026, with revenue of Rs. 2,229 Cr. and EBITDA of Rs. 268 Cr. The company's revenue grew by 17% YoY, driven by solid growth across all business segments, particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new & third line. However, EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which includes revenue from operations, other income, and expenses.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about a scheduled meeting with institutional investors and analysts on August 13-14, 2026, to discuss Q1'FY27 earnings presentation.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about General Updates - Newspaper advertisements titled 'Notice of 48th Annual General Meeting, E-voting, Record Date and Final Dividend Information'.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about General Updates - Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2025-26, if approved by the members at the ensuing AGM
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about General Updates-Intimation regarding letter(s) dispatched to the shareholders whose email IDs are not registered, for AGM Notice, TDS Communication and Annual Report of the Company for FY 2025-26.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has announced the notice of its 48th Annual General Meeting (AGM) to be held on August 26, 2026, through video conferencing. The meeting will consider the re-appointment of directors, dividend declaration, and other business. The company has also dispatched the AGM notice and annual report to its members.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has submitted copies of newspaper advertisements relating to the transfer of equity shares/dividend to the Investor Education and Protection Fund Authority.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about a notice of transfer of equity shares/dividend to the Investor Education and Protection Fund (IEPF) due to unclaimed dividends for 7 consecutive years.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about the submission of newspaper publications for the 48th Annual General Meeting scheduled to be held on August 26, 2026 through Video Conferencing/Other Audio Visual Means.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about the dispatch of postal ballot notices and publication of newspaper advertisements.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange regarding Notice of Postal Ballot for shareholders' approval through remote electronic voting.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has informed the Exchange about General Updates, specifically the Grant of 2,07,003 Stock Options/ Restricted Stock Units (RSUs) / Performance Stock Units (PSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.
Jubilant Pharmova Limited
Jubilant Pharmova Limited has received a rectification order from the Income Tax Department deleting a tax demand of Rs. 22.10 crores for Assessment Year 2020-21.